SCHEMBL13867366

SCHEMBL13867366

c1cc(OCC2CC2)cc(-c2cnc3ccc(OC4CCCCC4)nn23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 13/20 0.60
FYN P06241 2/20 0.51
MKNK1 Q9BUB5 4/20 0.46
MKNK2 Q9HBH9 1/20 0.46
DYRK1A Q13627 1/20 0.43
GAK O14976 1/20 0.43
STK10 O94804 1/20 0.43
YES1 P07947 1/20 0.43
RET P07949 1/20 0.43
PDGFRB P09619 1/20 0.43
CSNK2A2 P19784 1/20 0.43
FLT3 P36888 1/20 0.43
ACVR1 Q04771 1/20 0.43
KCNH2 Q12809 1/20 0.43
PKN1 Q16512 1/20 0.43
PIM3 Q86V86 1/20 0.43
HASPIN Q8TF76 1/20 0.43
SIK2 Q9H0K1 1/20 0.43
SLK Q9H2G2 1/20 0.43
BMP2K Q9NSY1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13867069 0.91 PIM1 (0.73) PIM1FYNMKNK1MKNK2KCNH2
SCHEMBL13867417 0.91 PIM1 (0.73) PIM1FYNMKNK1MKNK2KCNH2
SCHEMBL13867132 0.87 PIM1 (0.63) PIM1FYNDYRK1A
SCHEMBL19987066 0.84 PIM1 (0.84) PIM1DYRK1AKCNH2
SCHEMBL13867074 0.83 FYN (0.61) PIM1FYNMKNK1
SCHEMBL14372190 0.83 FYN (0.58) PIM1FYNDYRK1AGAKSTK10
SCHEMBL13867078 0.82 FYN (0.60) PIM1FYN
SCHEMBL23299238 0.82 PIM1 (0.60) PIM1FYNMKNK1MKNK2DYRK1A
SCHEMBL13867315 0.82 PIM1 (0.74) PIM1DYRK1AKCNH2
SCHEMBL13867316 0.81 PIM1 (0.55) PIM1FYNMKNK1MKNK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140135323-A1 OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-15 US disclosed
US-20140135323-A1 OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-15 US disclosed
US-8653076-B2 Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-18 US disclosed
US-8653076-B2 Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-18 US disclosed
US-20090093475-A1 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-04-09 US disclosed
US-20090093475-A1 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-04-09 US disclosed
WO-2007147646-A1 OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093475-A1 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals CDK2, CDK1, MAP4K2 PIM1 712/4885FYN 363/4885MKNK1 299/4885
US-20140135323-A1 OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS CDK2, CDK1, MAP4K2 PIM1 712/4885FYN 363/4885MKNK1 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.